Latest News Archive

Please select Category, Year, and then Month to display items

Prof Martin Nyaga champions Africa’s scientific leadership at the AAS Summit in Ghana

18 August 2025 | Story Somila Nazo | Photo Supplied

Prof Martin Nyaga, one of Africa’s foremost experts in genomics and global health, recently delivered a powerful call for Africa’s leadership in global science at the African Academy of Sciences (AAS) Summit in Accra, Ghana.

As Head of the Next Generation Sequencing (NGS) Unit at the University of the Free State (UFS) and Director of the WHO Collaborating Centre for Vaccine Preventable Diseases Surveillance and Pathogen Genomics, Prof Nyaga urged the scientific community to recognise Africa not just as a participant in global research, but as a driver of innovation and change.

A summit of vision and collaboration

Themed Unpacking the Pact for the Future: Imperatives for Advancing Scientific Cooperation with Africa, the summit took place from 2 – 4 July 2025. Hosted by the AAS in partnership with the African Union, the Government of Ghana, the University of Ghana, and other global partners, the summit brought together leading scientists, policymakers, and international stakeholders to discuss Africa’s role in shaping the future of global science, research and innovation.

The event was attended by high-level dignitaries, including the President of Ghana, His Excellency John Dramani Mahama, and the former President of Nigeria, His Excellency Olusegun Obasanjo – a clear indication of strong political will to prioritise science, health and innovation across the continent.

Advancing Africa’s voice in global health

On 2 July 2025, Prof Nyaga delivered his keynote address, Advances, Opportunities and Priorities for Global Health in Africa. He highlighted Africa’s growing capabilities in genomics and public health, underscoring the opportunities for scientific leadership.

Following his address, he joined an expert panel with representatives from Tanzania, Ghana and Nigeria to discuss strategies for advancing scientific cooperation in global health. His contributions focused on: strengthening research collaborations; building capacity within Africa; increasing African ownership in health innovations, and enhancing the translation of research into policy and practice.

Prof Nyaga also used the platform to spotlight the work of the UFS Next Generation Sequencing (UFS-NGS) Unit. As a WHO Collaborating Centre, the unit plays a critical role in pathogen tracking, monitoring vaccine-preventable diseases, and supporting public health preparedness across Africa and beyond.

“This engagement provided an opportunity to highlight the impactful research from the UFS-NGS Unit – not only in academic publications, but in demonstrating tangible public health benefits to policy makers,” said Prof Nyaga. “It elevated the University of the Free State’s standing as a leader in genomic science, while opening new opportunities for collaboration for South Africa and the continent. Our research priorities are increasingly shaping global health and innovation agendas.”

From Ghana to the G20

The outcomes of the summit will feed into a communiqué to be presented at the 2025 G20 Summit, to be hosted by South Africa. Prof Nyaga’s thought leadership ensures that Africa’s scientific voice - and South Africa’s research priorities - will be represented at one of the world’s most influential multilateral platforms.

For more information about UFS partnerships in Africa, contact the Office for International Affairs at partnerships@ufs.ac.za.

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept